$RNA News

Atrium Therapeutics Doses First Patient In Its Phase 1/2 Corventis Clinical Trial Evaluating ATR 1072 For Potential Treatment Of PRKAG2 Syndrome; Expects Initial Proof-Of-Concept Data In H2 2027

Roth Capital Initiates Coverage On Atrium Therapeutics with Buy Rating, Announces Price Target of $15

Atrium Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Yakira Capital Management Calls on Atrium Therapeutics to Launch Strategic Review, Curb Cash Spending and Explain Dilutive Financing

Shareholder Yakira Capital Urges Atrium Therapeutics To Explore Strategic Sale Or Partnerships, Citing 44% Stock Decline, $50M Dilutive Financing

Atrium: Initiating "Hold" ATR 1072 IND Clearance And 2nd Half 2027 PRKAG2 Syndrome Data

Atrium Therapeutics Announces $50 Million Private Placement

Atrium Therapeutics Announces $50M Private Placement Of 5,170,384 Shares And Pre-Funded Warrants To Purchase Up To 1,134,930 Shares At ~$7.93/Unit

Atrium Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Atrium Therapeutics to Participate in Upcoming Investor Conferences

HC Wainwright & Co. Reiterates Buy on Atrium Therapeutics, Maintains $25 Price Target

Atrium Therapeutics Q2 EPS $(1.18) Misses $(1.01) Estimate, Sales $3.004M Beat $2.000M Estimate

HC Wainwright & Co. Initiates Coverage On Atrium Therapeutics with Buy Rating, Announces Price Target of $25

Atrium Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Atrium Therapeutics Announces FDA Clearance of Investigational New Drug Application for ATR 1072 for Treatment of PRKAG2 Syndrome

Atrium Therapeutics Says FDA Clears IND Application Allowing It To Move Forward With Corventis Phase 1/2 Clinical Trial To Evaluate ATR 1072 For Treatment Of PRKAG2 Syndrome

Atrium Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Cantor Fitzgerald Initiates Coverage On Atrium Therapeutics with Overweight Rating, Announces Price Target of $25

Here's Why We're Not Too Worried About Atrium Therapeutics' (NASDAQ:RNA) Cash Burn Situation

Leerink Partners Initiates Coverage On Atrium Therapeutics with Outperform Rating, Announces Price Target of $25